Serositis as possible manifestation in MDS/AML patients with complex karyotype and TP53 mutation: case series
Four MDS/AML patients with specific genetic mutations and inflammatory fluid responded to steroids, alerting clinicians to immune manifestations of blood cancer.
A case series of 4 MDS/AML patients with TP53 mutations and complex karyotype who developed inflammatory serositis improved with corticosteroid treatment, highlighting autoinflammatory manifestations as a potential presentation of this high-risk MDS/AML subset. Immune dysregulation awareness may improve early diagnosis in this difficult-to-treat population.
What the study was
- Study design
- Case series (N=4)
- Population
- MDS/AML patients with TP53 mutation and complex karyotype; Italy
- Sample size
- 4
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Annals of Hematology
Why it surfaced
Small case series (N=4) describing autoinflammatory manifestation in high-risk MDS/AML. Capped by case series design (<5 rule). Relevant for clinical awareness but not pipeline-ready.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.